{"id":918214,"date":"2025-12-10T07:05:16","date_gmt":"2025-12-10T12:05:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/"},"modified":"2025-12-10T07:05:16","modified_gmt":"2025-12-10T12:05:16","slug":"cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/","title":{"rendered":"CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n PRINCETON, N.J.<\/span>
\n <\/span>, Dec. 10, 2025<\/span><\/span> \/PRNewswire\/ — CytoSorbents Corporation<\/a><\/u> (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that Dr. Phillip Chan<\/span>, CEO, and Peter J. Mariani<\/span>, CFO, will join Jason Kolbert<\/span>, Head of Healthcare Research at D. Boral Capital, for a virtual fireside chat. Building on the Company’s recent third quarter earnings call, highlighting $37.0 million<\/span> in trailing 12-month high-margin sales, a strengthened balance sheet, and ongoing regulatory progress for\u00a0DrugSorb\u2122-ATR with the U.S. Food and Drug Administration (FDA) and a key regulatory decision expected in mid-2026, the discussion will offer additional insight into these developments as well other important milestones shaping the Company’s next phase of expected growth.<\/p>\n

\n

\n
\n \"CytoSorbents
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Fireside Chat Details:<\/b>\n <\/p>\n

\n Title:<\/b>\u00a0Transforming Critical Care: CytoSorbents’ Blood-Purification Programs Deliver Growing Revenues as DrugSorb-ATR Moves Toward a Mid-2026 FDA Review
Date:<\/b>Monday, December 15, 2025<\/span>
Time:<\/b>11:00 AM<\/span> \u2013 12:00 PM EST<\/span>
Registration:<\/b>\u00a0D. Boral Capital \u2013 CytoSorbents<\/a><\/p>\n

\n About CytoSorbents Corporation (NASDAQ: CTSO)<\/b>\n <\/p>\n

\n CytoSorbents Corporation<\/a>\u00a0is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification.\u00a0CytoSorbents’\u00a0proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body.\u00a0CytoSorbents’\u00a0technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine storm and cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.<\/p>\n

CytoSorbents’\u00a0lead product,\u00a0CytoSorb<\/a>\u00ae<\/a>, is approved in the European Union and distributed in over 70 countries worldwide, with nearly 300,000 devices used cumulatively to date.\u00a0CytoSorb was originally launched in the\u00a0European Union\u00a0under CE mark as the first cytokine adsorber. Additional\u00a0CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for\u00a0ticagrelor<\/a>\u00a0and\u00a0rivaroxaban<\/a>\u00a0removal in cardiothoracic surgery procedures. CytoSorb has also received\u00a0FDA Emergency Use Authorization<\/a> in\u00a0the United States\u00a0for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure.\u00a0CytoSorb is not yet approved or cleared in\u00a0the United States<\/span>.<\/p>\n

In the\u00a0U.S.\u00a0and\u00a0Canada,\u00a0CytoSorbents\u00a0is developing the DrugSorb\u2122-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations<\/a>: one for the removal of ticagrelor<\/a>\u00a0and another for the removal of the\u00a0direct oral anticoagulants (DOAC) apixaban and rivaroxaban<\/a>\u00a0in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of\u00a0DrugSorb-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA.\u00a0DrugSorb-ATR is not yet granted or approved in either the\u00a0U.S.\u00a0or\u00a0Canada.<\/p>\n

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued\u00a0U.S.\u00a0and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY\u00ae, CytoSorb-XL\u2122, HemoDefend-RBC\u2122, HemoDefend-BGA\u2122, VetResQ\u00ae, K+ontrol\u2122, DrugSorb\u2122, ContrastSorb, and others. For more information, please visit the Company’s website at\u00a0https:\/\/ir.cytosorbents.com\/<\/a> and follow us on\u00a0Facebook<\/a>\u00a0and\u00a0X<\/a>\u00a0and\u00a0LinkedIn<\/a>.<\/p>\n

\n Forward-Looking Statements
<\/b>This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in\u00a0Germany, ability to successfully obtain\u00a0U.S.\u00a0FDA and\u00a0Health Canada\u00a0marketing authorization or approval, our ability to complete our strategic workforce and cost reduction plan to reduce costs, optimize operations, and achieve cash-flow break-even in the first quarter of 2026, our ability to appropriately finance the Company, and the risks discussed in our Annual Report on Form 10-K, filed with the\u00a0SEC\u00a0on\u00a0March 31, 2025, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.<\/p>\n

\u00a0Please Click to Follow Us on Facebook<\/a> and X<\/a><\/u><\/b><\/p>\n

\n U.S. Company Contact:<\/b>\u00a0
Peter J. Mariani<\/span>, Chief Financial Officer
305 College Road East
Princeton, NJ<\/span> 08540
pmariani@cytosorbents.com<\/a>\u00a0<\/p>\n

\n Investor Relations Contact:
<\/b>
\n Aman Patel<\/span>, CFA & Adanna G. Alexander<\/span>, PhD
ICR Healthcare\u00a0
ir@cytosorbents.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025-302637393.html<\/a><\/p>\n

SOURCE Cytosorbents Corp<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire PRINCETON, N.J. , Dec. 10, 2025 \/PRNewswire\/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that Dr. Phillip Chan, CEO, and Peter J. Mariani, CFO, will join Jason Kolbert, Head of Healthcare Research at D. Boral Capital, for a virtual fireside chat. Building on the Company’s recent third quarter earnings call, highlighting $37.0 million in trailing 12-month high-margin sales, a strengthened balance sheet, and ongoing regulatory progress for\u00a0DrugSorb\u2122-ATR with the U.S. Food and Drug Administration (FDA) and a key regulatory decision expected in mid-2026, the discussion will offer additional insight into these developments as well other important milestones shaping the … <\/p>\n

Continue reading “CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-918214","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PRINCETON, N.J. , Dec. 10, 2025 \/PRNewswire\/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that Dr. Phillip Chan, CEO, and Peter J. Mariani, CFO, will join Jason Kolbert, Head of Healthcare Research at D. Boral Capital, for a virtual fireside chat. Building on the Company’s recent third quarter earnings call, highlighting $37.0 million in trailing 12-month high-margin sales, a strengthened balance sheet, and ongoing regulatory progress for\u00a0DrugSorb\u2122-ATR with the U.S. Food and Drug Administration (FDA) and a key regulatory decision expected in mid-2026, the discussion will offer additional insight into these developments as well other important milestones shaping the … Continue reading "CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-10T12:05:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2754298\/CytoSorbents_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025\",\"datePublished\":\"2025-12-10T12:05:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\\\/\"},\"wordCount\":1080,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2754298\\\/CytoSorbents_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\\\/\",\"name\":\"CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2754298\\\/CytoSorbents_Logo.jpg\",\"datePublished\":\"2025-12-10T12:05:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2754298\\\/CytoSorbents_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2754298\\\/CytoSorbents_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/","og_locale":"en_US","og_type":"article","og_title":"CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 - Market Newsdesk","og_description":"PR Newswire PRINCETON, N.J. , Dec. 10, 2025 \/PRNewswire\/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that Dr. Phillip Chan, CEO, and Peter J. Mariani, CFO, will join Jason Kolbert, Head of Healthcare Research at D. Boral Capital, for a virtual fireside chat. Building on the Company’s recent third quarter earnings call, highlighting $37.0 million in trailing 12-month high-margin sales, a strengthened balance sheet, and ongoing regulatory progress for\u00a0DrugSorb\u2122-ATR with the U.S. Food and Drug Administration (FDA) and a key regulatory decision expected in mid-2026, the discussion will offer additional insight into these developments as well other important milestones shaping the … Continue reading \"CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-10T12:05:16+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2754298\/CytoSorbents_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025","datePublished":"2025-12-10T12:05:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/"},"wordCount":1080,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2754298\/CytoSorbents_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/","name":"CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2754298\/CytoSorbents_Logo.jpg","datePublished":"2025-12-10T12:05:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2754298\/CytoSorbents_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2754298\/CytoSorbents_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/918214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=918214"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/918214\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=918214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=918214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=918214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}